Results 1 to 10 of about 964 (152)

Drug-induced liver injury (DILI) - mechanisms and diagnostic [PDF]

Farmacja Polska, 2022
The drug-induced liver injury (DILI) is one of the leading causes of the liver disease in developed countries. These injuries may be the result of constant drug hepatotoxicity or idiosyncrasy associated with the drug or its metabolite.
Marta Małysz, Aleksandra Więcek, Małgorzata Piechaczek, Lucyna Beata Pomierny-Chamioło   +3 more
doaj   +3 more sources

Clinical management of patients with drug‐induced liver injury (DILI) [PDF]

United European Gastroenterology Journal, 2021
AbstractDrug‐induced liver injury (DILI) should be considered in all patients with recent elevation of liver tests without obvious etiology and normal hepatobiliary imaging. There is currently no biomarker that is helpful in diagnosis which relies on clinical and laboratory findings.
Einar S. Björnsson
openalex   +4 more sources

The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment [PDF]

Metabolites, 2022
Drug-induced liver injury (DILI) is one of the most frequent adverse clinical reactions and a relevant cause of morbidity and mortality. Hepatotoxicity is among the major reasons for drug withdrawal during post-market and late development stages, representing a major concern to the pharmaceutical industry.
Marta Moreno‐Torres, Alfonso Quintás‐Cardama, José V. Castell   +2 more
openalex   +6 more sources

Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes [PDF]

Archives of Toxicology, 2021
AbstractDrug-induced liver injury (DILI) is an adverse toxic hepatic clinical reaction associated to the administration of a drug that can occur both at early clinical stages of drug development, as well after normal clinical usage of approved drugs. Because of its unpredictability and clinical relevance, it is of medical concern. Three DILI phenotypes
Alfonso Quintás‐Cardama, Teresa Martínez-Sena, Isabel Conde, Eugenia Pareja, Jos Kleinjans, José V. Castell   +5 more
openalex   +5 more sources

Genetic variations in drug-induced liver injury (DILI): resolving the puzzle [PDF]

Frontiers in Genetics, 2012
Despite stringent requirements for drug development imposed by regulatory agencies, drug-induced liver injury (DILI) is an increasing health problem and a significant cause for failure to approve drugs, market withdrawal of commercialized medications, and adoption of regulatory measures.
Camilla Stephens, M. Isabel Lucena, Raúl J. Andrade   +2 more
openalex   +6 more sources

Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials [PDF]

Drug Safety, 2021
Causality assessment for suspected drug-induced liver injury (DILI) during drug development and following approval is challenging. The IQ DILI Causality Working Group (CWG), in collaboration with academic and regulatory subject matter experts (SMEs), developed this manuscript with the following objectives: (1) understand and describe current practices;
J. Hey‐Hadavi, Daniel Seekins, Melissa Palmer, Denise Coffey, John Caminis, Sandzhar Abdullaev, Meenal Patwardhan, Haifa Tyler, Ritu Raheja, Ann Marie Stanley, Liliam Pineda-Salgado, David L. Bourdet, Raúl J. Andrade, Paul H. Hayashi, Lara Dimick‐Santos, Don C. Rockey, Alvin Estilo   +16 more
openalex   +4 more sources

A Rare Case of Drug-Induced Liver Injury (DILI) From Topiramate

Cureus
A 72-year-old male individual with a past medical history of seizures and ongoing management with topiramate for two months presented at the emergency department with jaundice. Ten days before the presentation, the patient started feeling fatigued and had intermittent generalized mild pain (grade 3/10) with dark-brown discoloration of urine.
Raymart Macasaet, FNU Payal, Karan Yagnik, Malay Rathod, David Aquino, Shilpan Shah   +5 more
openalex   +3 more sources

Models of Drug Induced Liver Injury (DILI) – Current Issues and Future Perspectives [PDF]

Current Drug Metabolism, 2018
Drug-induced Liver Injury (DILI) is an important cause of acute liver failure cases in the United States, and remains a common cause of withdrawal of drugs in both preclinical and clinical phases.A structured search of bibliographic databases - Web of Science Core Collection, Scopus and Medline for peer-reviewed articles on models of DILI was performed.
Lucija Kuna, Ivana Božić, Tomislav Kizivat, Kristina Bojanić, Margareta Mrso, Edgar Kralj, Robert Smolić, George Y. Wu, Martina Smolić   +8 more
openalex   +3 more sources

Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug‐induced idiosyncratic liver injury (DILI) [PDF]

British Journal of Pharmacology, 2007
Background and purpose:The general view on the pathogenesis of drug‐induced idiosyncratic liver injury (DILI) is that parent compounds are rendered hepatotoxic by metabolism, mainly by cytochrome (CYP) 450, although other metabolic pathways can contribute. Anecdotal reports suggest a role of CYP 450 polymorphisms in DILI. We aimed to assess in a series
Ketevan Pachkoria, M. Isabel Lucena, Francisco Ruíz-Cabello, Esperanza Crespo, M.R. Cabello, Raúl J. Andrade   +5 more
openalex   +6 more sources

The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury [PDF]

Expert Review of Gastroenterology & Hepatology, 2017
Drug-induced liver injury (DILI) is challenging for drug development, clinical practice and regulation. The Liver Toxicity Knowledge Base (LTKB) provides essential data for DILI study. Areas covered: The LTKB provided various types of data that can be used to assess and predict DILI.
Shraddha Thakkar, Minjun Chen, Hong Fang, Zhichao Liu, Ruth Roberts, Weida Tong   +5 more
openalex   +4 more sources